Biosimilar Denosumab

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

About Richter Gedeon

Richter Gedeon's mission is to improve patient lives through the research, development, and global commercialization of innovative pharmaceuticals. The company has achieved a dominant position in its core Central and Eastern European markets while expanding its international footprint, supported by a robust pipeline of 34 candidates. Its strategy is built on deep therapeutic expertise in women's health and CNS, vertical integration from API to finished product, and a disciplined approach to both organic R&D and strategic partnerships to fuel sustainable growth.

Therapeutic Areas

Other Osteoporosis, Bone Metastasis Drugs